Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Pharmacoeconomics - Open|February 12, 2019
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Rui Duarte, et al.
Pharmacoeconomics - Open|June 27, 2019
Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, James Mahon, Sarah Nevitt, et al.
Health Technology Assessment (Winchester, England)|June 27, 2014
Allopurinol for the treatment of chronic kidney disease: a systematic reviewNigel Fleeman, Gerlinde Pilkington, Yenal Dundar, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pharmacoeconomics - Open|September 21, 2023
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, et al.
Pharmacoeconomics|November 28, 2017
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Ahmed Abdulla, Adrian Bagust, et al.
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Personalized Medicine|May 20, 2018
Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifenNigel Fleeman, Katherine Payne, William G Newman, et al.
Pharmacoeconomics - Open|April 21, 2023
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachel Houten, Nigel Fleeman, James Mahon, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Pageof 4